昆山亚香香料股份有限公司 重大信息内部报告制度 昆山亚香香料股份有限公司 第一章 总则 第一条 为规范昆山亚香香料股份有限公司（以下简称"公司"）重大信息内 部报告工作，保证公司内部重大信息的快速传递、归集和有效管理，及时、准确、 全面、完整地披露信息，维护投资者的合法权益，根据《中华人民共和国公司法》、 《中华人民共和国证券法》、 《上市公司信息披露管理办法》、 《深圳证券交易所创 《深圳证券交易所上市公司自律监管指引第 2 号——创业板 业板股票上市规则》、 上市公司规范运作》以及《公司章程》等有关规定，结合公司实际，制定本制度。 第二条 公司重大信息内部报告制度是指当出现、发生或即将发生可能对公 司股票及其衍生品种交易价格产生较大影响的情形或事件时，按照本制度规定负 有报告义务的单位、部门、人员，应当在第一时间将相关信息向公司责任领导、 董事会秘书进行报告的制度。 第三条 本制度适用于公司各部门及子公司。 第二章 重大信息报告义务人 第四条 本制度所称报告义务人为： （一）公司的董事、高级管理人员； （二）公司各部门负责人、子公司负责人； （三）公司控股股东、实际控制人，持有公司 5%以上股份的其他股东 ...

昆山亚香香料股份有限公司 内部审计制度 第三条 本制度所称内部审计，是指由公司内部机构或人员，对公司内部控 制和风险管理的有效性、财务信息的真实性和完整性以及经营活动的效率和效果 等开展的一种评价活动。包括监督被审计对象的内部控制制度运行情况，检查被 审计对象会计账目及相关资产及企业经营状况，监督被审计对象预决算执行和财 务收支，评价重大经济活动的效益等行为。 第四条 本制度所称内部控制制度，是指公司董事会、高级管理人员及其他 有关人员为实现下列目标而提供合理保证的过程： （一）遵守国家法律、法规、规章及其他相关规定； 昆山亚香香料股份有限公司 第一章总则 第一条 为规范并保障公司内部审计监督，提高审计工作质量，实现内部审 计经常化、制度化，发挥内部审计工作在加强内部控制管理、促进企业经济管理、 提高经济效益中的作用，根据《中华人民共和国审计法》、 《审计署关于内部审计 工作的规定》、 《中国内部审计准则》等法律、法规及深圳证券交易所的有关规定 和《昆山亚香香料股份有限公司章程》 （以下简称"公司章程"），特制定本制度。 第二条 本制度所称被审计对象，特指公司各内部机构、控股子公司及具有 重大影响的参股公司。 ...

昆山亚香香料股份有限公司 关联交易管理制度 昆山亚香香料股份有限公司 第一章 总则 第一条 为完善昆山亚香香料股份有限公司（以下简称公司或股份公司）的 法人治理结构，规范关联交易，充分保障商事活动的公允、合理，维护公司及股 东利益，依据《中华人民共和国公司法》等相关法律法规及《昆山亚香香料股份 有限公司章程》（以下简称《公司章程》）的规定，并参照中国证监会《上市公 司治理准则》、《上市公司股东会规则》、《深圳证券交易所创业板股票上市规则》 等规定，并结合本公司实际情况，特制订本制度。 第二章 关联交易 第二条 本规则所述的关联交易，是指股份公司或其控股子公司与股份公司 关联人之间发生的转移资源、权利或者义务的事项，包括有偿交易行为及无对价 的转移行为。 第三条 关联人和关联关系 （1）直接或间接控制股份公司的法人； （2）由上述第（1）项法人直接或间接控制的除股份公司及其控股子公司以 外的法人； （3）持有股份公司5%以上股份的法人； （4）本制度所指的关联自然人直接或间接控制的或担任董事、高级管理人 员的，除股份公司及其控股子公司以外的法人； （5）中国证监会、证券交易所或者股份公司根据实质重于形式的原则认 ...

Core Viewpoint - Asia Aroma Co., Ltd. (亚香股份) has announced a cash dividend and a stock bonus plan for its shareholders, reflecting its commitment to returning value to investors while also adjusting its capital structure [3][4]. Trading Information Summary - As of May 19, 2025, Asia Aroma's stock closed at 68.52 yuan, down 3.21%, with a turnover rate of 7.29% and a trading volume of 34,400 shares, resulting in a total transaction value of 236 million yuan [1]. - On the same day, the net inflow of main funds was 10.87 million yuan, accounting for 4.61% of the total transaction value, while retail investors saw a net inflow of 14.75 million yuan, making up 6.26% of the total [2][4]. Company Announcement Summary - The company will distribute a cash dividend of 2 yuan (including tax) for every 10 shares held, totaling 15,985,420 yuan (including tax), and will also increase its capital by issuing 4 additional shares for every 10 shares held, resulting in a total increase of 31,970,840 shares [3][4]. - The total share capital after the bonus issue will be 112,770,840 shares, with the record date for the dividend set for May 23, 2025, and the ex-dividend date on May 26, 2025 [3].

证券代码：301220 证券简称：亚香股份 公告编号：2025-034 (2) 按公司总股本（含回购股份）折算的每 10 股转增股数=本次转增股份数量 /总股本×10=31,970,840 股/80,800,000 股×10 股=3.956787 股，即每股转增股数为 司总股本折算的每股现金红利）/（1+按公司总股本折算的每股转增股数）=（除权除 息前一交易日收盘价-0.1978393）/（1+0.3956787）。 公司 2024 年年度权益分派方案已获 2025 年 5 月 14 日召开的 2024 年年度股东大 会审议通过，现将权益分派事宜公告如下： 一、股东大会审议通过利润分配方案情况 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 参与本次权益分派。本次权益分派将以公司现有总股本 80,800,000 股剔除已回购股份 实际派发现金分红总额 15,985,420.00 元（含税），同时以资本公积金向全体股东每 10 股转增 4 股，合计转增 31,970,840 股，转增后公司总股本为 112,770,840 股。 利、每 10 股资本公 ...

Core Viewpoint - The company reported a mixed financial performance for 2024, with revenue growth but a significant decline in net profit, indicating challenges in maintaining profitability amidst competitive pressures in the market [1][2]. Financial Performance - In 2024, the company achieved a revenue of 797 million yuan, a year-on-year increase of 26.42%, while the net profit attributable to shareholders was 56 million yuan, down 30.51% year-on-year [1]. - The company's gross profit margin for 2024 was 25.52%, a decrease of 6.65 percentage points compared to the previous year [2]. - The net profit margin for 2024 was 6.90%, down 5.71 percentage points year-on-year, reflecting increased competition and reduced profit margins [2]. Cash Flow and Financial Health - The net cash flow from operating activities in 2024 was 31 million yuan, a decrease of 58.75% year-on-year, primarily due to rising product costs and increased procurement expenses [3]. - The net cash flow from investing activities was -284 million yuan, a decline of 433.73% year-on-year, attributed to the disposal of financial assets and investment returns [3]. - The net cash flow from financing activities increased to 133 million yuan, up 700.33% year-on-year, mainly due to increased bank borrowings [3]. Market Position and Product Offering - The company is a leading producer of mid-to-high-end flavoring agents in China, with a diverse product range including over 310 types of flavors, meeting various downstream application needs [4]. - The company has established stable relationships with major international flavor companies, ensuring a solid customer base and revenue growth [5]. - The global flavor and fragrance market is projected to grow, with the market size expected to reach approximately 32.1 billion USD by 2025, indicating a favorable environment for the company's growth [5][6]. Strategic Initiatives - The company is expanding its overseas market presence to mitigate geopolitical risks, with a new synthetic vanillin production line planned in Thailand [7]. - The Thai production facility has commenced full operations, contributing to performance growth, while domestic capacity expansion is underway [7]. - The company is adapting to new tariffs on imports, implementing a production adjustment plan to maintain competitiveness [7]. Future Outlook - The company is expected to achieve revenues of 1.406 billion yuan, 1.762 billion yuan, and 2.007 billion yuan for 2025-2027, with corresponding net profits of 223 million yuan, 294 million yuan, and 352 million yuan [8]. - The company is well-positioned to benefit from the expanding flavor and fragrance market and its new production capacities, leading to improved economic efficiency [8].

| 招商证券股份有限公司 | | | | | --- | --- | --- | --- | | 关于昆山亚香香料股份有限公司 | | | | | 保荐人名称：招商证券股份有限公司 | 被保荐公司简称：亚香股份 | | | | 联系电话：0755-83084021 保荐代表人姓名：覃建华 | | | | | 保荐代表人姓名：程建新 联系电话：0755-83084021 | | | | | 一、保荐工作概述 | | | | | 项目 工作内容 | | | | | （1）是否及时审阅公司信息披露文件 | | 是 | | | （2）未及时审阅公司信息披露文件的次数 | | | 无 | | （1）是否督导公司建立健全规章制度（包括但 | | | | | 不限于防止关联方占用公司资源的制度、募集资 | | | | | 是 | | | | | 金管理制度、内控制度、内部审计制度、关联交 | | | | | 易制度） | | | | | （2）公司是否有效执行相关规章制度 | | 是 | | | （1）查询公司募集资金专户次数 | | 8次 | | | （2）公司募集资金项目进展是否与信息披露文 | | | | | 是 | ...

Core Viewpoint - The company has experienced significant revenue growth in 2024, but net profit has declined due to intense price competition in the spice industry [2] Group 1: Financial Performance - In 2024, the company achieved a revenue of 797 million yuan, representing a year-on-year increase of 26.42%, while net profit attributable to shareholders was 56 million yuan, down 30.51% [2] - In Q1 2024, the company reported a record revenue of 262 million yuan and a net profit of approximately 82.17 million yuan, with a non-recurring net profit of 38.20 million yuan, marking a year-on-year growth of 120.8% [2] Group 2: Production Capacity and Expansion - The first phase of the "Yaxiang Biotechnology (Thailand) Co., Ltd. Production Base Project" commenced production in November 2024, with the Thai factory achieving normal full-load production [2] - The first phase capacity includes 1,000 tons of vanillin, 200 tons of oak moss, and other products, with a second phase expected to be completed around August 2025 [3] - A new synthetic vanillin production line is planned in Thailand, which will have an annual capacity of 4,000 tons [3] Group 3: Strategic Investments - The company plans to acquire 10% equity in Centrome Inc. for 30 million USD to expand sales channels and market share in the U.S. [3] - This investment is expected to enhance the company's international influence and complement its U.S. subsidiary's operations [3] Group 4: Market Strategy - The establishment of the Thai base allows the company to diversify its product structure and increase production capacity while avoiding tariff impacts [4] - The company is actively exploring new product layouts to meet diverse market demands, including the introduction of ambroxan, a fragrance ingredient commonly used in perfumes [4]

Group 1: Financial Performance - The company's net profit for 2024 is expected to decline due to four main factors: increased fixed asset depreciation, a 37% year-on-year increase in sales team size leading to higher sales expenses, increased R&D investment, and a structural decline in gross margin of core products due to intensified market competition [2][3] - In Q1 2025, the company reported a net profit growth of approximately 360%, attributed to investment income of about 40 million yuan and the efficient operation of the Thai production base [3] Group 2: Operational Insights - The Thai factory achieved approximately 90 million yuan in revenue and 19 million yuan in net profit in Q1 2025, primarily producing vanillin and cooling agents [3] - Long-term contracts account for about 80% of the company's total revenue, with pricing strategies adjusted based on market supply and demand dynamics [3][4] Group 3: Expansion and Product Development - The first phase of the Thai base is fully operational, with the second phase expected to be completed around August 2025, and the third phase in preliminary planning [3] - The company is actively exploring new product developments, such as ambroxan, to meet diverse market and consumer demands [4] - Strategic investment in ABT shares aims to strengthen sales channels and enhance market competitiveness [4]

Financial Performance - In Q1 2025, the company achieved operating revenue of 97.79 million, a year-on-year increase of 24.06% [2] - The net profit attributable to shareholders in Q1 2025 was 11.45 million, reflecting a year-on-year growth of 94.50% [2] - For the full year 2024, the company reported operating revenue of 345.18 million, up 28.12% compared to the previous year [3] - The net profit attributable to shareholders for 2024 was 22.09 million, showing a significant increase of 659.83% [3] Strategic Focus - The company plans to enhance its core competencies in product innovation, brand strength, and quality control to drive future profitability [4] - Emphasis will be placed on market-oriented R&D, focusing on technology iteration, new product development, and quality improvement [3] Market Challenges - The ongoing US-China tariff conflict has had a measurable impact on the company's performance [4] - The company is actively exploring new regional markets to reduce reliance on any single market and mitigate tariff impacts [5] - Strategies include enhancing internal management and cost control to improve product competitiveness [5] R&D Investment - The company is committed to increasing R&D investment to foster technological breakthroughs and product innovations [3] - Future R&D efforts will focus on optimizing management systems, enhancing innovation efficiency, and developing new technologies in emerging sectors [3]